Sfoglia per AUTORE
RICCI V
Collezione AO Cuneo
Items : 18
Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib. in Vaccines / Vaccines (Basel). 2023 Feb 2;11(2):335. doi: 10.3390/vaccines11020335.
2023
AO Cuneo
Abbona A; Ricci V; Paccagnella M; Granetto C; Ruatta F; Cauchi C; Galizia D; Ghidini M; Denaro N; Merlano MC; Garrone O;
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. in Vaccines / Vaccines (Basel). 2021 Mar 8;9(3):235. doi: 10.3390/vaccines9030235.
2021
AO Cuneo
Basiricò M; Gammaitoni L; Galizia D; Crosetto N; Bertetto O; Merlotti A; Ruatta F; Denaro N; Fea E; Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Merlano MC; Sangiolo D; Aglietta M; Garrone O;
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. in British journal of cancer / Br J Cancer. 2021 Jan;124(1):183-190. doi: 10.1038/s41416-020-01089-9. Epub 2020 Oct 7.
2021
AO Cuneo
AOU Città della Salute di Torino
Falcone A; Cremolini C; Rapisardi S; Masi G; Latiano TP; Moretto R; Pietrantonio F; Ritorto G; Buonadonna A; Zaniboni A; Caponnetto S; Ricci V; Bergamo F; Ermacora P; Germani MM; Antoniotti C; Tomasello G; Santini D; Lonardi S; Rossini D;
Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy. in Tumori / Tumori. 2020 Oct;106(5):427-431. doi: 10.1177/0300891620942313. Epub 2020 Jul 23.
2020
AO Cuneo
Crosetto N; Colantonio I; Di Costanzo G; Fea E; Ricci V; Cauchi C; Occelli M; Vandone AM; Granetto C; Vanella P; Ruatta F; Denaro N; Garrone O; Merlano MC;
Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. in World journal of gastrointestinal oncology / World J Gastrointest Oncol. 2020 Mar 15;12(3):301-310. doi: 10.4251/wjgo.v12.i3.301.
2020
AO Cuneo
Ricci V; Granetto C; Falletta A; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano MC;
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.
2019
AO Cuneo
Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C;
Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib in Annals of Oncology
2019
AO Cuneo
Ricci V; Falletta A; Granetto C; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano M;
Correlation between values of specific biomarkers and outcome in metastatic colorectal cancer patients treated with regorafenib in Annals of Oncology
2019
AO Cuneo
AOU Città della Salute di Torino
Ricci V; Falletta A; Granetto C; Paccagnella M; Abbona A; Fea E; Fabozzi T; Lo Nigro C; Merlano M; Zucchelli G; Marmorino F; Rossini D; Aprile G; Casagrande M; Lonardi S; Murgioni S; Dell'Aquila E; Tomasello G; Moretto R; Antoniotti C; Borelli B; Urbano F; Ronzoni M; Zaniboni A; Manglaviti S; Buonadonna A; Ritorto G; Masi G; Allegrini G; et alii...
Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies in Journal of Clinical Oncology
2019
AO Cuneo
AOU Città della Salute di Torino
Zucchelli G; Moretto R; Schirripa M; Intini R; Rossini D; Santini D; Pizzo C; Antoniotti C; Borelli B; Marmorino F; Urbano F; Burgio V; Libertini M; Prisciandaro M; Buonadonna A; Bustreo S; Allegrini G; Ricci V; Cremolini C; Falcone A;
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.
2018
AOU Città della Salute di Torino
AO Cuneo
Boni L; Zagonel V; Di Donato S; Ricci V; Allegrini G; Buonadonna A; Racca P; Zaniboni A; Tomasello G; Ronzoni M; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Lonardi S; Antoniotti C; Del Re M; Cremolini C; Falcone A; Danesi R;
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. in BMC cancer / BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.
2017
AO Cuneo
Santini D; Allegrini G; Di Donato S; Passardi A; Tomasello G; Valsuani C; Pietrantonio F; Ronzoni M; Ricci V; Tamburini E; Aprile G; Lonardi S; Zagonel V; Boni L; Schirripa M; Salvatore L; Antoniotti C; Masi G; Loupakis F; Marmorino F; Cremolini C; Falcone A;
Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. in Oncology letters / Oncol Lett. 2017 Feb;13(2):979-983. doi: 10.3892/ol.2016.5523. Epub 2016 Dec 20.
2017
AO Cuneo
Fasano M; Fabozzi A; Giordano G; Venturini F; Aurilio G; Cantile F; Fabozzi T; Ricci V; Santabarbara G; Morgillo F; Ciardiello F; De Vita F;
Correlation between the prognostic value of tumor-infiltrating lymphocytes (TILS) and sidedness in colorectal cancer (CC) patients (pts) in Annals of Oncology
2017
AO Cuneo
Granetto C; Ricci V; Fea E; Vivenza D; Lo Nigro C; Fortunato M; Comino A; Merlano M;
Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group in Journal of Clinical Oncology
2017
AO Cuneo
Rossini D; Moretto R; Cremolini C; Zagonel V; Tonini G; Ricci V; Aprile G; Lonardi S; Tomasello G; Dell'Aquila E; Allegrini G; Bergamo F; Mancini M; Antoniotti C; Ronzoni M; Zaniboni A; Marmorino F; Bustreo S; Mori E; Falcone A;
Heterogeneity of colon cancer: from bench to bedside. in ESMO open / ESMO Open. 2017 Aug 22;2(3):e000218. doi: 10.1136/esmoopen-2017-000218. eCollection 2017.
2017
AO Cuneo
Garrone O; Ricci V; Fea E; Merlano MC; Granetto C;
Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer in Annals of Oncology
2016
AO Cuneo
Ricci V; Comino A; Vivenza D; Granetto C; Lo Nigro C; Ferrero M; Merlano MC;
Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies in Journal of Clinical Oncology
2016
AO Cuneo
Casagrande M; Moretto R; Loupakis F; Cremolini C; Masi G; Borelli B; Lonardi S; Marsico VA; Ferrari L; Ricci V; Grande R; Tomasello G; Ronzoni M; Allegrini G; Tonini G; Mancini ML; Zaniboni A; Chiara S; Carlomagno C; Falcone A;
Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC) in Annals of Oncology
2015
AO Cuneo
Ricci V; Vivenza D; Monteverde M; Strola G; Granetto C; Lo Nigro C; Merlano MC;